decisionhealth Newsletters, Part B News - 2016 Issue 3 (March)
New Part B drug pay models intended to boost quality would test providers
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS proposed rule for a nationwide Medicare Part B drug payment test and explains how the demonstration would be structured across phases and provider groups. It is relevant to physicians, hospitals, compliance staff, and billing professionals who follow Medicare payment policy, especially those involved with office- and outpatient-administered drugs. The discussion includes the overall purpose of the test, the types of providers and settings affected, the timing of the proposal, geographic participation details, and administrative processes tied to the model.
Why This Topic Matters
The proposal could affect how Medicare pays for many Part B drugs and may change financial incentives for participating providers and facilities. Understanding the rule is important for organizations that bill for drug administration in office or outpatient settings and for those monitoring CMS innovation and payment policy.
What You Will Learn
- The purpose and scope of CMS’s proposed Part B drug payment test
- How the demonstration is structured across multiple phases
- Which provider settings and broad drug categories are affected or excluded
- How value-based payment tools are incorporated into the later phase of the model
- What implementation and comment-timing details are included in the proposal
Who Should Read This
- Physicians
- Hospitals and outpatient facilities
- Medical billing and coding professionals
- Practice managers
- Compliance and reimbursement staff
- Healthcare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com